Filing summary: Edge Therapeutics, Inc. Form 10-K
Entity discrepancy: The request identifies PDS Biotechnology Corp., but the supplied filing is for Edge Therapeutics, Inc. (Nasdaq: EDGE). This summary covers the supplied filing, for the fiscal year ended December 31, 2017, filed March 1, 2018.
Business context and reporting period
Edge was a clinical-stage biotechnology company with no approved products or product revenue. Its lead candidate, EG-1962, is an investigational sustained-release nimodipine formulation for aneurysmal subarachnoid hemorrhage (aSAH), then in Phase 3 testing. Other candidates, EG-1964 and EG-1965, were in preclinical development. The company reported 2017 results against 2016.
Financial and operating metrics
| Metric | 2017 | 2016 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $34.3 million | $24.8 million |
| General and administrative expense | $17.7 million | $14.7 million |
| Total operating expenses | $52.0 million | $39.5 million |
| Net loss | $50.9 million | $38.8 million |
| Net loss per share, basic and diluted | $1.67 | $1.34 |
| Cash and cash equivalents at year-end | $88.1 million | $106.4 million |
| Net cash used in operating activities | $40.7 million | $32.2 million |
There were no sales-based margins to assess. Cash used in investing activities was $0.2 million; financing activities provided $22.6 million, including $17.4 million net proceeds from a registered direct stock offering and $5.0 million of debt proceeds. At year-end, total assets were $92.6 million, current liabilities $12.9 million, and debt principal outstanding $20.0 million. The loan carried a 9.15% effective rate at year-end and was secured by substantially all assets except intellectual property. Management reported no off-balance-sheet arrangements.
Material changes versus 2016
- Net loss increased 31% to $50.9 million, while operating expenses rose 32% to $52.0 million.
- R&D expense increased 38%, primarily reflecting higher EG-1962 development costs and additional personnel; G&A rose 20%.
- Operating cash use increased by $8.5 million, and year-end cash declined $18.3 million despite equity and debt financing.
- In 2017, the company drew the final $5.0 million tranche under its Hercules loan and raised $17.4 million net through an equity offering.
Outlook, commentary, risks, and unusual items
- The independent data monitoring committee recommended that the NEWTON 2 Phase 3 study continue after a planned futility analysis of the first 150 treated patients. The company expected an interim analysis by the end of April 2018 and, absent an overwhelmingly positive result, anticipated full study results in late 2018. The committee’s recommendation did not establish efficacy.
- Management said existing cash was expected to fund anticipated requirements for at least 12 months from the filing’s reporting context, but cautioned that estimates depend on assumptions and that additional capital would be needed to advance and potentially commercialize candidates.
- Key risks include Phase 3 failure or further trial requirements; potential delay from Nymalize’s orphan exclusivity through May 2020 or competing nimodipine products; reliance on Oakwood and single-source suppliers; manufacturing scale-up and regulatory compliance; reimbursement and market adoption; and the need for additional financing.
- The Hercules loan’s interest-only period and maturity were extended in January 2018 to September 1, 2018 and August 3, 2020, respectively. The debt includes covenants, a maturity fee, and prepayment charges.
- The Tax Cuts and Jobs Act reduced the federal corporate tax rate; the company recorded a corresponding reduction in deferred tax assets offset by its full valuation allowance. It also sold New Jersey tax losses and credits for $2.6 million in 2017, reported as an income tax benefit.
- Management assessed disclosure controls and internal control over financial reporting as effective at December 31, 2017. The auditor did not provide an internal-control attestation, consistent with the company’s emerging-growth-company exemption.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is Edge Therapeutics, not PDS Biotechnology.
- Review the full NEWTON 2 interim and final results, including clinical outcomes, safety, analysis population, and whether regulators require additional trials.
- Assess cash burn, financing needs, loan repayment schedule and covenants, and the feasibility of the stated cash runway.
- Evaluate manufacturing capacity and single-source supply exposure, plus the potential effect of orphan exclusivity and competing products on EG-1962’s approval and launch timing.
- Reconcile a balance-sheet presentation discrepancy: selected financial data lists 2017 stockholders’ equity of $63.4 million, while the audited balance sheet reports $62.4 million.